← Back to patent-cliff list

Vilanterol Trifenatate

Tier C — Watch / trade

Vilanterol Trifenatate

GSK
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:ADRB2

Indications (approved):Asthma, Chronic obstructive pulmonary disease

Regional status

US
Phase III
2009-09-25
EU
No progress
2009-09-25
China
No progress
2011-01-25
Japan
No progress
2009-10-05

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 13 · Total yield 4.3 g
VILA-01178191-00-1VILA-01254030-34-1VILA-013102293-80-1VILA-014452339-70-7VILA-015452339-71-8VILA-016452339-72-9VILA-00120443-98-5VILA-00285309-91-7VILA-003629-03-8VILA-004503070-57-3VILA-005452339-73-0VILA-006503068-36-8VILA-007503068-37-9VILA-008595-91-5VILA-0092316-64-5VILA-01052113-69-6API · Vilanterol Trifenatate
CodeCAS No.Intermediate
VILA-01178191-00-1AvailableN-methoxy-N-methylacetamide
VILA-01254030-34-11-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethan-1-one
VILA-013102293-80-12-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethan-1-one
VILA-014452339-70-7-
VILA-015452339-71-8tert-butyl (2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-oxoethyl)carbamate
VILA-016452339-72-9tert-butyl (R)-(2-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-hydroxyethyl)carbamate
VILA-00120443-98-52-(bromomethyl)-1,3-dichlorobenzene
VILA-00285309-91-72-((2,6-dichlorobenzyl)oxy)ethan-1-ol
VILA-003629-03-81,6-dibromohexane
VILA-004503070-57-32-((2-((6-bromohexyl)oxy)ethoxy)methyl)-1,3-dichlorobenzene
VILA-005452339-73-0(R)-5-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2-one
VILA-006503068-36-8(R)-3-(6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)-5-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2-one
VILA-007503068-37-9(R)-2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethan-1-ol
VILA-008595-91-52,2,2-triphenylacetic acid
VILA-0092316-64-54-bromo-2-(hydroxymethyl)phenol
VILA-01052113-69-66-bromo-2,2-dimethyl-4H-benzo[d][1,3]dioxine

Frequently asked questions

What are the approved indications of Vilanterol Trifenatate?

Approved indications include: Asthma, Chronic obstructive pulmonary disease.

When does the Vilanterol Trifenatate patent expire?

No public expiry year is available for Vilanterol Trifenatate yet; this page updates once verified.

How many synthesis routes are recorded for Vilanterol Trifenatate?

1 synthesis routes are recorded; the shortest is 13 steps with 4.3 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Vilanterol Trifenatate intermediates?

1 intermediate CAS of Vilanterol Trifenatate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Vilanterol Trifenatate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21